Rejuvenate Biomed

Rejuvenate Biomed is a science-based healthy aging company dedicated to the discovery and development of therapeutics to impact the onset of multiple age-related diseases. The company is conducting a Phase 2 clinical trial of its lead asset RJx-01, a first-in-class multi-pathway therapeutic targeting COPD-induced sarcopenia and muscle weakness, with topline data expected by year-end 2026.